FEMY Stock Performance, Insider Transaction and News

FEMY - Femasys Inc.

Market Cap	8.45M	P/E	-	EPS this Y	16.10%	Ern Qtrly Grth	-
Income	-14.25M	Forward P/E	-1.00	EPS next Y	43.60%	50D Avg Chg	-5.00%
Sales	1.07M	PEG	-	EPS past 5Y	-	200D Avg Chg	-42.00%
Dividend	N/A	Price/Book	0.54	EPS next 5Y	-	52W High Chg	-75.00%
Recommedations	2.00	Quick Ratio	7.22	Shares Outstanding	22.10M	52W Low Chg	76.00%
Insider Own	7.64%	ROA	-40.62%	Shares Float	19.87M	Beta	-2.99
Inst Own	6.42%	ROE	-84.82%	Shares Shorted/Prior	1.19M/1.12M	Price	0.56
Gross Margin	64.55%	Profit Margin	-	Avg. Volume	3,658,606	Target Price	9.75
Oper. Margin	-2,087.89%	Earnings Date	-	Volume	840,597	Change	-4.82%

Healthcare | Medical Instruments & Supplies | United States

About Femasys Inc.

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Femasys Inc. News

04/18/24	Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
03/31/24	Femasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
03/28/24	Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
03/21/24	Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
03/20/24	Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
03/13/24	Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
03/06/24	Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
02/28/24	Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
02/06/24	Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
01/26/24	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
01/23/24	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
12/15/23	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
11/30/23	Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
11/28/23	30 Countries with the Lowest Median Age in the World
11/28/23	Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
11/23/23	20 Countries with the Highest Teenage Pregnancy Rates
11/15/23	PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
11/15/23	Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
11/14/23	Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
10/30/23	12 Best Stocks For Day Trading

FEMY Chatroom

Dodgemuscle Posted - 2 hours ago

$FEMY may 9 is not light years away it is right around the corner

Dodgemuscle Posted - 2 hours ago

$FEMY question:earnings report are may 9 revenue estimate was 1.4 million now I see it is 860 or 840 still 4 times that of many of the previous quarters what will happen to the stock price if it hits or goes above the estimate what are yiur thoughts bluesir or anyone else

goldenxb Posted - 3 hours ago

$FEMY again, another situation in which FemBloc could become very popular

Dodgemuscle Posted - 5 hours ago

$FEMY eye captain lt blunderstock reporting from the engine room we have taken a direct hit sir we are receiving water down here oh dhit we just got hit again what should we do nothing the replies we have all the shareholders money in an offshore Swiss account let her sink mate man the life boats

Dodgemuscle Posted - 6 hours ago

$FEMY no volume nothing no interest anymore has totally lost its luster blame the company for that Noone really knows about the company and when they look at tge last 45 days hah would you invest in a sinking ship

donutfish Posted - 9 hours ago

$FEMY Every time one of these boards starts getting full of posts about "smart money" and "tutes" and "weak hands" I know it's a bullshit stock. So far so good here.

Dodgemuscle Posted - 13 hours ago

$FEMY this was 2 bucks just s few weeks ago brutal

Itzana Posted - 16 hours ago

$FEMY one day shorts will be sorry. 🙏🏼

Dodgemuscle Posted - 17 hours ago

$FEMY shorting tge bejesusus put if this it will go to the otc soon and then once they burn thru the 5 million bankrupt city

Dodgemuscle Posted - 17 hours ago

$FEMY the company says does nothing no striking good news nothing they suck no clinical study news nothing about sales nothing to stimulate the stock price nothing to stimulate investors

Dodgemuscle Posted - 17 hours ago

$FEMY if it goes below 1.10 I can buy blue sir a lambo not new used low miles

Dodgemuscle Posted - 17 hours ago

$FEMY nice day for shorters shame it did not plummet below 1.24 she wanted to

TripTrap Posted - 19 hours ago

$FEMY Okay so this makes a lot of sense… FemaSeed is going to completely disrupt the IUI / IVF space this year and in @ 2 years or so no women will be tying their tubes because of FemBloc. So let’s just take FEMY’s price down to zero howbout… ? Well this makes ZERO sense… beyond frustrated…

ididathing9999 Posted - 1 day ago

$FEMY That was funny. Someone put in a market 12121 sale and HFTs dumped on them with the thin bid/ask spread causing the sale to execute at $1.21 for a slippage loss of ~$1200.